Mitomo Hideyuki, Kato Ryo, Ito Akiko, Kasamatsu Shiho, Ikegami Yoji, Kii Isao, Kudo Akira, Kobatake Eiry, Sumino Yasuhiro, Ishikawa Toshihisa
Department of Biomolecular Engineering, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259 Nagatsuta, Midori-ku, Yokohama, 226-8501, Japan.
Biochem J. 2003 Aug 1;373(Pt 3):767-74. doi: 10.1042/BJ20030150.
Overexpression of the ATP-binding cassette transporter ABCG2 reportedly causes multidrug resistance, whereas altered drug-resistance profiles and substrate specificity are implicated for certain variant forms of ABCG2. At least three variant forms of ABCG2 have been hitherto documented on the basis of their amino acid moieties (i.e., arginine, glycine and threonine) at position 482. In the present study we have generated those ABCG2 variants by site-directed mutagenesis and expressed them in HEK-293 cells. Exogenous expression of the Arg(482), Gly(482), and Thr(482) variant forms of ABCG2 conferred HEK-293 cell resistance toward mitoxantrone 15-, 47- and 54-fold, respectively, as compared with mock-transfected HEK-293 cells. The transport activity of those variants was examined by using plasma-membrane vesicles prepared from ABCG2-overexpressing HEK-293 cells. [Arg(482)]ABCG2 transports [(3)H]methotrexate in an ATP-dependent manner; however, no transport activity was observed with the other variants (Gly(482) and Thr(482)). Transport of methotrexate by [Arg(482)]ABCG2 was significantly inhibited by mitoxantrone, doxorubicin and rhodamine 123, but not by S -octylglutathione. Furthermore, ABCG2 was found to exist in the plasma membrane as a homodimer bound via cysteinyl disulphide bond(s). Treatment with mercaptoethanol decreased its apparent molecular mass from 140 to 70 kDa. Nevertheless, ATP-dependent transport of methotrexate by [Arg(482)]ABCG2 was little affected by such mercaptoethanol treatment. It is concluded that Arg(482) is a critical amino acid moiety in the substrate specificity and transport of ABCG2 for certain drugs, such as methotrexate.
据报道,ATP结合盒转运蛋白ABCG2的过表达会导致多药耐药,而ABCG2的某些变体形式则与耐药谱和底物特异性的改变有关。迄今为止,基于ABCG2第482位的氨基酸部分(即精氨酸、甘氨酸和苏氨酸),已记录了至少三种ABCG2变体形式。在本研究中,我们通过定点诱变产生了这些ABCG2变体,并在HEK-293细胞中进行表达。与mock转染的HEK-293细胞相比,ABCG2的Arg(482)、Gly(482)和Thr(482)变体形式的外源性表达分别使HEK-293细胞对米托蒽醌的耐药性提高了15倍、47倍和54倍。通过使用从过表达ABCG2的HEK-293细胞制备的质膜囊泡来检测这些变体的转运活性。[Arg(482)]ABCG2以ATP依赖的方式转运[(3)H]甲氨蝶呤;然而,其他变体(Gly(482)和Thr(482))未观察到转运活性。米托蒽醌、阿霉素和罗丹明123可显著抑制[Arg(482)]ABCG2对甲氨蝶呤的转运,但S -辛基谷胱甘肽则无此作用。此外,发现ABCG2以通过半胱氨酸二硫键结合的同型二聚体形式存在于质膜中。用巯基乙醇处理可使其表观分子量从140 kDa降至70 kDa。然而,[Arg(482)]ABCG2对甲氨蝶呤的ATP依赖转运几乎不受这种巯基乙醇处理的影响。结论是,Arg(482)是ABCG2对某些药物(如甲氨蝶呤)的底物特异性和转运中的关键氨基酸部分。